Investigational Site Number :6880001

Belgrade 11000

3 studies enrolling now · 9 studies all time

What they study most

Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Crohn's Disease, Glycogen Storage Disease Type II, Polyneuropathy, Inflammatory Demyelinating, Chronic, Pompe Disease, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Type 2 Diabetes Mellitus, Ulcerative Colitis

Studies at this site

• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Pompe Disease Registry Protocol — Recruiting now
• Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP — Enrolling by invitation
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) — Completed
• Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early